Technical Content - Aragen Bioscience

Technical Content

Article

View all

Propelling Glioblastoma Research: Aragen Bioscience’s Orthotopic Model Solutions

DSS-induced IBD Mouse Model for preclinical drug screening

RSV Challenge Model for anti-RSV therapy

Oncology solutions: Accelerate your cancer therapeutics development

Preclinical evaluation of Novel drug candidates against SLE in NZB/W F1 mouse models

Bleomycin-Induced Scleroderma mouse model for preclinical testing of novel therapeutics

Cell Line Development : Research cell banks in 5 months

Mitigating CMC issues through holistic approach to developability assessment

Industry Leading Hybridoma Technique for Accelerated Antibody Discovery

A Comparative Efficiency Analysis of Commercial Transfection Reagents in HEK 293 Cells

View all

Brochure

View all

Your partner for timely, accurate and high-quality preclinical efficacy studies

Resin recycling studies

Gene to GMP: First-in-human in 8 Months with Optimized Cost

Cell Line Development Solutions for Biologics CHO CLD Platforms

Comprehensive Solutions for Animal Health Biologics

Preclinical Oncology Capabilities

Preclinical Evaluation of new Antifibrotics in IPF Rodent Models

Integrated Cell Line Development Solutions

Developability and Analytics Solutions

Protein Analytics Solutions

Comprehensive Characterization of Biologics

Protein science solutions: Industry leading upstream and downstream capabilities

View all

Case Studies

View all

A Pre-clinical Study for Diet-induced Obesity

Unravelling Immunological Depths: Exploring Oxazolone-induced Delayed-Type Hypersensitivity Model

Unlocking Insights: A Translational Mouse Model for Non-Genetic Heterotopic Ossification

Getinge Single-use Bioreactor (SUPR) Fed-batch Production Runs

Expression, in vivo Maturation and Tag-less Purification of a Recombinant Protein

An optimal upstream process development approach to increase the titers of the monoclonal antibodies (mAbs)

View all

Posters

View all

Selective ROCK2 inhibitor ameliorates established dermal and pulmonary fibrosis in murine systemic sclerosis and shifts the balance between Th17 and Treg cells in vivo

Novel Technique for Quick and Easy Aggregate Removal of Monoclonal Antibodies Using Competitive Binding on CEX

Enhancing mAb platform process using Membrane chromatography (Affnity/Protein-A, using Sartobind Rapid A) for FIH molecules with focus on Optimizing cost and Accelerating timelines

View all

Webinar

View all

Upstream Process Development for Better Yield and Product Quality

The Role of Protein Analytics in the Advancement of Biotherapeutic Drug Discovery & Development

Driving Better titers and Shorter Timelines with a Robust and Scalable CHO DG44 Platform

Brain Metastases – Challenges of Developing Clinically Relevant Preclinical Models

Accelerating Biologics Development to Medicines: Key Drivers of Success

View all

Learn more about our end-
to-end capabilities

✽

✽

✽

✽

✽

✽

✽

By submitting this form you agree to our Privacy Policy concerning the way Aragen bioscience may use your personal information.

BACK TO TOP